Engineered anti-tslp antibody
AssigneeSchering Corporation
InventorsLeonard G. Presta, Rene de Waal Malefyt
Life of this patent
Estimating the term…
Abstract
The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
Claims25
-3. (canceled)
A binding compound that specifically binds human and cyno TSLP, wherein the binding compound comprises:
- the three CDR sequences set forth in SEQ ID NOs:
- 1, 2 and 3;
- and
- the three CDR sequences set forth in SEQ ID NOs:
- 4, 5 and 6.
-6. (canceled)
(canceled)
-17. (canceled)
An antibody that specifically binds to the epitope on human TSLP that is bound by the antibody produced by the hybridoma deposited as PTA-7951, wherein the antibody that specifically binds to the epitope on human TSLP is not the antibody produced by the hybridoma deposited as PTA-7951.
An antibody that competitively inhibits binding by the antibody produced by the hybridoma deposited as PTA-7951 to human TSLP, wherein the antibody that competitively inhibits binding is not the antibody produced by the hybridoma deposited as PTA-7951.
-33. (canceled)
Dependencies are inferred from the claim text.